Condition: Lung Cancer · Gene Abnormality · Gene Product Sequence Variation · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD,PhD · +86-020-34153532 · zhangzhf@gzhmu.edu.cn
Deji Chen, MD,PhD · +86-020-34153532 · chendeji2003@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03192501